Oncotelic’s Subsidiary Sapu Nano to Showcase Deciparticle Nanomedicine Platform at BIO‑Europe Spring 2026
+0.0%
March 24, 2026 | By BeyondSPX Newsroom
Sapu Nano, a subsidiary of Oncotelic Therapeutics, will present its Deciparticle platform and clinical pipeline at BIO‑Europe Spring 2026 on March 25, 2026, following an announcement made on March 24.